No material corporate news briefings were recorded for Amgen Inc. in the 30 days preceding this report's generation date of 2026-06-17. The report is principally driven by notable institutional position changes recorded in recent 13F filings, supplemented by the most recent quarterly financial data and insider transaction records [Brief - 2026-06-09].
Amgen's trailing twelve-month revenue stood at $37.22 billion as of 31 March 2026, reflecting 5.76% year-over-year growth, while net income for the same period was $7.80 billion, producing a net margin of 20.96% [SEC 10-Q - AMGN - 2026-03-31]. Gross margin was recorded at 48.58% and operating margin at 28.39%. EPS grew 4.38% year-over-year. The company held $12.04 billion in cash against total debt of $59.32 billion. Market capitalisation was approximately $187.73 billion and the trailing P/E ratio was 24.21 [SEC 10-Q - AMGN - 2026-03-31].
Insider activity in June 2026 comprised 11 transactions with a mixed net direction and a net value of zero, indicating no dominant disposition or acquisition trend among insiders during the period [SEC Form 4 - AMGN - 2026-06]. Institutional activity showed notable divergence: Bridgewater added 389% to its reported AMGN position, while Millennium added 47% [SEC 13F - Bridgewater - Q1 2026; SEC 13F - Millennium - Q1 2026]. Conversely, AQR Capital reduced its position by 30% and Citadel reduced its position by 9.4% [SEC 13F - AQR Capital - Q1 2026; SEC 13F - Citadel - Q1 2026].
The prevailing macro environment reflected a 10-year US Treasury yield of 4.47% and a 2-year yield of 4.07%, producing a normal yield curve configuration [FRED DGS10; FRED DGS2]. This report was generated in response to material institutional position changes identified across multiple 13F filers in the most recent reporting period.